It was first described in a November 2020 preprint by a team including members of Wuhan Institute of Virology and Vigonvita.

[3] Results from a separate Phase 3 trial conducted in mainland China from October 2022 to January 2023 suggested that deuremidevir may shorten the duration of COVID-19 symptoms in non-hospitalized adults with mild-to-moderate disease compared to placebo.

[4] Junshi, which markets the drug, received conditional approval from China's National Medical Products Administration in January 2023.

[5][6] In November 2023, in response to viral mutations and changing characteristics of infection, the WHO adjusted its treatment guidelines.

[7] In preclinical studies, a single high dose of the drug (at least 1.0 g/kg) was shown to be tolerated in rats and dogs.